Nimesulide drug
was launched in Italy for
the first time as Aulin and Mesulid in 1985 and is presently
available in more than 50 countries worldwide with different
trademarks.
Nimesulide is used for the treatment of
post-traumatic inflammation, acute musculoskeletal disorders
including sprains, strains, tendinitis, tenosynovitis, low back pain,
periarthritis (shoulder pain) and osteoarthritis (joint pains),
stiffness.
Nimesulide brands
such as Sulide, Nimalox, Nimesil,
Nimulid, Nicip, Nimcap, Nise, Sulidene
and Zolan.
It has superior gastrointestinal safety
as compared to other NSAIDs.
It is an analgesic and antipyretic in
action. Its multifactorial mode of action gives
it a unique and broad action on inflammatory processes.
The maximum
duration and dose of a treatment course with Nimesulide medicine is
15 days, 100 mg twice a day, to minimize the risk of hepatotoxicity.
Nimesulide also improves the skin tone
and to increase in energy levels. Food, gender
and advanced age have negligible effects on Nimesulide
pharmacokinetics.
Unlike, other NSAIDs, the chemical
structure of nimesulide does not contain a carboxylic group but a
sulfonanilide moiety as the acidic group.
It undergoes
extensive biotransformation and has a relatively rapid onset of
action, with meaningful reductions in pain and inflammation observed
within 15 minutes from drug intake.
No comments:
Post a Comment